Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form (ICF) that meets all criteria of current Food and Drug Administration (FDA) regulations.~* Females aged 30-75 years inclusive who are postmenopausal, defined as follows:~* At least 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) level of \>40 milli-international units per milliliter (mIU/mL); at least 6 weeks post-surgical bilateral oophorectomy, with or without hysterectomy; or hysterectomy without oophorectomy if of age that the Investigator believes would have been naturally reached 12 months of spontaneous amenorrhea.~* Vaginal pH \>5.0.~* At least 1 of the following participant self-assessed moderate to severe symptoms of vulvar and vaginal atrophy (VVA) from the following list that is identified by the participant as being most bothersome to her:~  1. Vaginal Dryness~ 2. Vaginal and/or vulvar irritation/itching~ 3. Dysuria~ 4. Vaginal pain or bleeding associated with sexual activity, provided that participant is currently sexually active and plans to remain so throughout study.~* Normal Screening mammogram completed within 9 months prior to Screening in all participants \>40 years old.~* Normal clinical breast examination at the Screening Visit.~* Documented papanicolaou (PAP) smear conducted within the previous 12 months with no findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.~* Participants with an intact uterus should have vaginal ultrasonography results to confirm an inactive endometrial lining, defined as endometrial thickness less than 4 millimeters (mm).~Exclusion Criteria:~1. Females younger than 30 years of age or older than 75 years of age.~2. Participants with a Serum follicle-stimulating hormone (FSH) level of ≤40 mIU/mL at Screening.~3. Greater than 5% superficial cells on vaginal cytology.~4. Vaginal pH ≤5.~5. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder (including significant liver/kidney impairment) or other medical condition that in the Investigator's opinion would place the study participant at undue risk by participation or could jeopardize the integrity of the study evaluations.~6. Participants with an intact uterus should have vaginal ultrasonography results to confirm an inactive endometrial lining. Participants with an endometrial thickness equal to or greater than 4 mm.~7. Documented PAP smear conducted within the previous 12 months with findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.~8. Participants with known concurrent vaginal infections including but not limited to:~   Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, or Gardnerella vaginalis.~9. Participants with active vaginal herpes simplex infection or have had an outbreak within 30 days of the first dosing day.~10. Participants with known, suspected, or current history of carcinoma of the breast. All participants over the age of 40 must have had a mammogram performed within 9 months of the study start and all participants will have a physical breast exam performed at Screening.~11. Participants with known, suspected or current history of hormone dependent tumor.~12. Participants with baseline systolic blood pressure of \>150 millimetres of mercury (mmHg) and/or diastolic pressure \>90 mmHg.~13. Any participant with undiagnosed vaginal bleeding or significant risk factors for endometrial cancer.~14. Any history of estrogen-dependent neoplasia (for example, endometrial cancer).~15. History of acute thrombophlebitis or thromboembolic disorder.~16. Any current or recent (within the previous 6 months) genital bleeding of unknown etiology.~17. Any prescription treatment or over-the-counter (OTC) or natural remedies for vaginal dryness/irritation within 28 days of Screening. Products used for lubrication during sexual intercourse within 7 days of Screening.~18. Participants whose fasting triglyceride levels are greater than 350 mg/dL.~19. Any participant with a history of radiation therapy or recent (within previous 6 weeks) surgical therapy to the vaginal or cervical areas.~20. Any known or suspected allergies that in the Investigator's opinion would compromise the safety of the participant.~21. Participants who have used vaginal hormonal products (rings, creams, gels) within the 28 days prior to Screening.~22. Any participant who has used transdermal estrogen and/or progestin therapy within the 28 days prior to Screening.~23. Participants who have used oral estrogen and/ or progestin therapy or intrauterine progestin therapy within the 56 days prior to Screening.~24. Participants who have used progestin implants or estrogen alone injectable drug therapy within the 3 months before Screening.~25. Participants who have used estrogen pellet therapy or progestin injectable drug therapy within the 6 months before Screening.~26. Participants who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.~27. Participants who are unable or unwilling to give informed consent.~28. Receipt of any drug as part of a research study within 30 days prior to Screening.~29. Participants who have participated in this study previously.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Generic Estradiol Vaginal Cream USP, 0.01% (Type: EXPERIMENTAL): Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
- Estrace Vaginal Cream USP, 0.01% (Type: ACTIVE_COMPARATOR): Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
- Vehicle Vaginal Cream (Type: PLACEBO_COMPARATOR): Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete